Last reviewed · How we verify
Chromic Chloride In Plastic Container (CHROMIC CHLORIDE)
Chromic Chloride, marketed by Pfizer, is a TPN supplement that uniquely targets the inhibition of Tyrosine-protein kinase Fyn, positioning it in a niche but critical segment of the market. Its key strength lies in the protection of its composition patent, which does not expire until 2028, providing a significant barrier to generic competition. The primary risk is the competitive landscape, with multiple drugs targeting the same mechanism, including acalabrutinib, afatinib, amivantamab, astemizole, and axitinib, all of which are either already on the market or have strong patent protections.
At a glance
| Generic name | CHROMIC CHLORIDE |
|---|---|
| Sponsor | Pfizer |
| Target | Epidermal growth factor receptor, Tyrosine-protein kinase Fyn |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1986 |
Approved indications
- TPN Supplement
- Prevent Chromium Deficiency
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |